kicked off on Monday, with Cognition Therapeutics Inc (NASDAQ: CGTX) stock price up 7.67% from the previous day of trading, before settling in for the closing price of $0.45. CGTX’s price has ranged from $0.34 to $2.95 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 52.79%. With a float of $33.67 million, this company’s outstanding shares have now reached $59.85 million.
Considering the fact that the conglomerate employs 28 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cognition Therapeutics Inc (CGTX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cognition Therapeutics Inc is 18.96%, while institutional ownership is 12.28%. The most recent insider transaction that took place on Jan 31 ’25, was worth 30,001. In this transaction CEO & President of this company bought 38,851 shares at a rate of $0.77, taking the stock ownership to the 38,851 shares.
Cognition Therapeutics Inc (CGTX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 52.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.97% during the next five years compared to -16.44% drop over the previous five years of trading.
Cognition Therapeutics Inc (NASDAQ: CGTX) Trading Performance Indicators
Here are Cognition Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.86, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.95 in one year’s time.
Technical Analysis of Cognition Therapeutics Inc (CGTX)
Compared to the last year’s volume of 1.71 million, its volume of 0.61 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 74.85%. Additionally, its Average True Range was 0.05.
During the past 100 days, Cognition Therapeutics Inc’s (CGTX) raw stochastic average was set at 13.96%, which indicates a significant decrease from 99.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.82% in the past 14 days, which was lower than the 96.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5827, while its 200-day Moving Average is $0.8198. Nevertheless, the first resistance level for the watch stands at $0.5032 in the near term. At $0.5166, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.5432. If the price goes on to break the first support level at $0.4632, it is likely to go to the next support level at $0.4366. Should the price break the second support level, the third support level stands at $0.4232.
Cognition Therapeutics Inc (NASDAQ: CGTX) Key Stats
With a market capitalization of 30.35 million, the company has a total of 41,548K Shares Outstanding. Currently, annual sales are 0 K while annual income is -25,790 K. The company’s previous quarter sales were 0 K while its latest quarter income was -9,940 K.
